Product: Anti-DcR2 /TRAIL-R4 (IN), Polyclonal
Cat. No: PC-010 (100 μg)
Background:
Apoptosis is induced by certain cytokines
including TNF and Fas ligand in the TNF family
through their death domain containing receptors.
TRAIL/Apo2L is a new member of the TNF
family and induces apoptosis of a variety of
tumor cell lines. DR4 and DR5 are the recently
identified functional receptors for TRAIL, and
DcR1/TRID is a decoy receptor. Another
member of the TRAIL receptor family was more
recently identified and designated DcR2, TRAILR4,
or TRUNDD. DcR2 has an extracellular
TRAIL-binding domain but lacks intracellular
death domain and does not induce apoptosis.
Like DR4 and DR5, DcR2 transcript is widely
expressed in normal human tissues.
Overexpression of DcR2 attenuated TRAILinduced
apoptosis.
Specificity:
Binds human DcR2 (TRAIL-R4).
Positive Control: HeLa whole cell lysate.
Species Reactivity:
Human, other species not tested.
Ig Isotype:
Rabbit IgG
Immunogen:
A peptide corresponding to amino acids 249 to
263 of human DcR2 precursor.
Format:
Affinity chromatography purified IgG, 100 μg in
200 μl of PBS containing 0.02% sodium azide.
Storage and Stability:
Stable for one year at 2-8°C. Store long term at -
20°C. Aliquot to avoid freeze/thaw cycles.
Applications and Suggested Dilutions:

Western blot: Suggested dilution: 1:1000 to
1:2000.
The optimal dilution for a specific application
should be determined by the researcher.
Limitations:
For in vitro research use only. Not for use in
diagnostics or in humans.
Warranty:
No warranties, expressed or implied, are made
regarding the use of this product. KAMIYA
BIOMEDICAL COMPANY is not liable for any
damage, personal injury, or economic loss
caused by this product